GPU-based sorting algorithms have emerged as a crucial area of research due to their ability to harness the immense parallel processing power inherent in modern graphics processing units.

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp (a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront.